{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-168287","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.360341+00:00","generated_at":"2026-05-15T04:56:45.195636+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"medium","headline":"Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial","bullets":["KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.","KYSA-8 registrational trial of miv-cel in stiff person syndrome achieved positive primary analysis results.","Conference call held April 22, 2026 to review both data sets; slides furnished as Exhibit 99.1.","Data presented at AAN 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-168287","json":"https://secwatch.observer/filing/0001193125-26-168287.json","markdown":"https://secwatch.observer/filing/0001193125-26-168287.md","text":"https://secwatch.observer/filing/0001193125-26-168287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/0001193125-26-168287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/d100817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:56:45.195636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}